X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (125) 125
humans (109) 109
male (64) 64
hematology (50) 50
female (49) 49
middle aged (36) 36
adult (35) 35
oncology (35) 35
aged (34) 34
adolescent (20) 20
animals (19) 19
imatinib mesylate (19) 19
prognosis (19) 19
treatment outcome (18) 18
abridged index medicus (16) 16
aged, 80 and over (16) 16
genetics & heredity (16) 16
analysis (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - genetics (14) 14
benzamides (13) 13
cancer (13) 13
cell biology (12) 12
child (12) 12
gene (12) 12
in situ hybridization, fluorescence (12) 12
phenotype (12) 12
young adult (12) 12
antineoplastic agents - therapeutic use (11) 11
apoptosis (11) 11
chemotherapy (11) 11
follow-up studies (11) 11
fusion proteins, bcr-abl - genetics (11) 11
imatinib (11) 11
mice (11) 11
minimal residual disease (11) 11
tumors (11) 11
chronic myelogenous leukemia (10) 10
expression (10) 10
leukemia (10) 10
survival (10) 10
therapy (10) 10
chronic myeloid-leukemia (9) 9
disease-free survival (9) 9
mutation (9) 9
piperazines - therapeutic use (9) 9
pyrimidines - therapeutic use (9) 9
research (9) 9
retrospective studies (9) 9
reverse transcriptase polymerase chain reaction (9) 9
signal transduction (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
bcr-abl (8) 8
biochemistry & molecular biology (8) 8
bone marrow (8) 8
child, preschool (8) 8
disease (8) 8
gene expression regulation, neoplastic (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
leukemia, myeloid, acute - genetics (8) 8
survival analysis (8) 8
survival rate (8) 8
translocation, genetic (8) 8
transplantation (8) 8
care and treatment (7) 7
case-control studies (7) 7
chronic myeloid leukemia (7) 7
cml (7) 7
identification (7) 7
in-situ hybridization (7) 7
patients (7) 7
philadelphia chromosome (7) 7
time factors (7) 7
wt1 proteins - genetics (7) 7
acute lymphoblastic-leukemia (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
biomarkers, tumor - metabolism (6) 6
blotting, western (6) 6
cell proliferation (6) 6
down-regulation (6) 6
gene expression (6) 6
growth (6) 6
hematology, oncology and palliative medicine (6) 6
infant (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - pathology (6) 6
minimal-residual-disease (6) 6
multidisciplinary sciences (6) 6
mutations (6) 6
neoplasm staging (6) 6
polymerase chain reaction (6) 6
recurrence (6) 6
surgery (6) 6
abnormalities, multiple - genetics (5) 5
activation (5) 5
acute disease (5) 5
acute myeloid leukemia (5) 5
acute myeloid-leukemia (5) 5
antigens, cd - analysis (5) 5
antineoplastic agents - pharmacology (5) 5
base sequence (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal Article
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 4
Journal Article
Microbiome, ISSN 2049-2618, 06/2017, Volume 5, Issue 1, pp. 66 - 66
Journal Article
Cell Host & Microbe, ISSN 1931-3128, 07/2018, Volume 24, Issue 1, pp. 133 - 145.e5
Journal Article
Journal Article
La radiologia medica, ISSN 0033-8362, 8/2017, Volume 122, Issue 8, pp. 623 - 632
Journal Article
Blood, ISSN 0006-4971, 06/2007, Volume 109, Issue 11, pp. 4635 - 4640
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 355 - 362
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression‐free survival (PFS) and overall survival (OS) in multiple... 
SURVIVAL | THERAPY | METAANALYSIS | EFFICACY | INITIAL TREATMENT | PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | HEMATOLOGY | YOUNGER | TRANSPLANTATION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Pyrazines - administration & dosage | Drug Evaluation | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Male | Case-Control Studies | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Aged, 80 and over | Female | Retrospective Studies | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Bortezomib | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Thalidomide - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Nervous System Diseases - chemically induced | Aged | Multiple Myeloma - genetics | Evidence, Expert | Medical research | Corticosteroids | Analysis | Multiple myeloma | Medicine, Experimental | Prednisone | Consulting services | Multivariate analysis | Chemotherapy | Ovarian cancer | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article